Symptomatic Control of Neuroendocrine Tumors with Everolimus Abstract #451

Introduction: Everolimus prolongs progression-free survival, but previous research has not demonstrated its effect on symptoms.
Aim(s): To evaluate the effect of everolimus on symptomatic control of neuroendocrine tumors.
Materials and methods: Fifteen patients with metastatic neuroendocrine disease pre-treated with depot octreotide received combination Everolimus and Octreotide (midgut=8, PNET=3, other=4). Reasons for initiation of Everolimus were progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) (n=5), worsening syndromic symptomatology (n=5), and both (n= 5). Symptomatic response and toxicity were evaluated using standard criteria.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Hannah Bainbridge

To read results and conclusion, please login ...

Further abstracts you may be interested in

#334 Everolimus + Octreotide LAR v. Placebo + Octreotide LAR in Patients With Advanced NET: Results of a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial (RADIANT-2)
Introduction: Everolimus, an oral inhibitor of mTOR, demonstrated promising antitumor activity in patients with NET as a single agent and in combination with octreotide LAR in two phase 2 studies.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Marianne Pavel
#133 Effectiveness of transarterial embolization of liver neuroendocrine metastases
Introduction: Neuroendocrine tumors (NETs) with diffuse liver metastases have a poor prognosis and prove difficult to palliate. Somatostatin analogues and chemotherapy have been used but often are poorly tolerated and may not provide symptom relief. Transarterial Embolization (TAE) is being increasingly used to improve symptom control and reduce tumor size. We looked at the last 5-year experience of TAE in patients with hepatic metastases from neuroendocrine tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Dalvinder S Mandair
#325 Effect of Everolimus + Octreotide LAR Treatment on 5-Hydroxyindoleacetic Acid Levels in Patients With Advanced Neuroendocrine Tumors: Phase III RADIANT-2 Study Results
Introduction: Urinary 5-hydroxyindoleacetic acid (5-HIAA) is a metabolite and surrogate measure of plasma serotonin, an important cause of carcinoid syndrome in patients with neuroendocrine tumors (NET).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Eric Baudin
#1203 Atypical Bronchial Carcinoid: Different Therapeutical Approachs
Introduction: Choosing an adequate treatment for atypical bronchial carcinoid can improve quality of life and survival.
Conference: 12th Annual ENETS Conference (2015)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Llanos Geraldo Roig
Authors: Geraldo Roig L, ...
#1238 Use of Everolimus in a Patient with Metastatic Bronchial Carcinoid Receiving Hemodialysis.
Introduction: Renal impairment may alter the normal pharmacokinetic and pharmacodynamic behavior of chemotherapy drugs, thus increasing the risk of side effects. Everolimus was reported to have anti-tumor activity in bronchial neuroendocrine tumors (NET). Safety and toxicity profile of everolimus has been provided in hemodialyzed patients with renal cell carcinoma. Only a report describes the effect of everolimus in a patient with metastatic ileac carcinoid in hemodialysis.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD Maria Pia Brizzi